Serial liquid biopsy data
- AACR26 presenters reported results from serial plasma comprehensive genomic profiling (pCGP) in NSCLC patients. - They observed 36% actionable alterations in treatment‑naïve patients and 22% received matched therapy within 30 days. - The findings show liquid biopsy can rapidly match therapies and reveal evolving resistance mechanisms like RAS/MET amplifications. (x.com)
Researchers at AACR 2026 reported that serial plasma comprehensive genomic profiling (pCGP) in 718 non‑small cell lung cancer patients guided treatment decisions and flagged resistance mutations. (aacrjournals.org 1) (aacrjournals.org 2) The single‑center retrospective study analyzed 818 pCGP instances from 718 patients collected 2015–2022, with 79 patients (11%) having longitudinal (serial) pCGP. (aacrjournals.org 1) (aacrjournals.org 2) Investigators found pCGP uniquely informed management in 92 patients (13%)—often when tissue genotyping wasn’t available—and in an EGFR‑mutant subgroup (n=214) detected PI3K pathway changes (11%), BRAF V600E (3%), and MET exon 14 skipping (3%). (aacrjournals.org) (aacrjournals.org) After progression on EGFR tyrosine kinase inhibitors, 31 EGFR‑mutant patients (22%) had actionable pCGP findings and 18 of those (58%) were matched to targeted therapy. (aacrjournals.org) (aacrjournals.org) pCGP is a blood test that sequences tumor DNA shed into plasma to look for hundreds of genomic changes at once; it’s faster and less invasive than repeat tissue biopsy and is already used to help select targeted treatments. (nature.com) The study’s authors reported that receipt of genotype‑matched therapy informed by pCGP was associated with significantly improved overall survival in their cohort. (aacrjournals.org) Experts and prior reviews note limits: liquid biopsy can be nondetectable when tumors shed little DNA, and it does not replace tissue for histology or some biomarker tests. (jtocrr.org) The presenters concluded serial pCGP can both accelerate therapy matching when tissue is unavailable and reveal evolving, targetable resistance mechanisms—findings released alongside their AACR 2026 presentations and concurrent journal publication on April 19, 2026. (aacrjournals.org) ( )
